Scarica l'app Stockscreener
26.49
1.07%
0.28
Dopo l'orario di chiusura:
26.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$26.21
Aprire:
$26.04
Volume 24 ore:
3.68M
Relative Volume:
1.84
Capitalizzazione di mercato:
$5.01B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-6.7923
EPS:
-3.9
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
-3.64%
1M Prestazione:
+14.97%
6M Prestazione:
-2.07%
1 anno Prestazione:
-30.65%
Intervallo 1D:
$26.02
$26.90
Intervallo di 1 settimana:
$25.34
$28.18
Portata 52W:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
26.49 | 5.01B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Geode Capital Management LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Wellington Management Group LLP Decreases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma's SWOT analysis: innovative pipeline drives stock potential - Investing.com
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Lifted by Barclays PLC - MarketBeat
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth By Investing.com - Investing.com South Africa
BridgeBio's SWOT analysis: genetic disease specialist's stock poised for growth - Investing.com Australia
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest Position - MarketBeat
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP - BioCentury
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Yahoo Finance
Learn to Evaluate (BBIO) using the Charts - Stock Traders Daily
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Frazier Life Sciences Management L.P. Buys 127,853 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4%Should You Buy? - MarketBeat
Polar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Janus Henderson Group PLC Increases Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Melqart Asset Management UK Ltd Grows Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HighVista Strategies LLC Acquires 24,482 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Unnatural Products Announces BridgeBio Exercises Option to - GlobeNewswire
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for - The Bakersfield Californian
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - Yahoo Finance
Erste Asset Management GmbH Invests $3.50 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma (BBIO) Stock Surges on FDA Approval of Lead Treatment - Nasdaq
BridgeBio Pharma (FRA:2CL) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
The week in pharma: action, reaction and insight – week to November 29 - The Pharma Letter
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More - Yahoo Finance
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - MSN
Intech Investment Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - MSN
HC Wainwright Has Optimistic Outlook of BBIO FY2024 Earnings - MarketBeat
Research Analysts Offer Predictions for BBIO FY2024 Earnings - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate - Morningstar
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings? - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - News & Insights
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Nov 19 '24 |
Sale |
22.41 |
4,156 |
93,137 |
93,758 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):